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Renal function markers and insulin
sensitivity after 3 years in a healthy cohort,
the EGIR-RISC study
Soline Siméon1, Ziad Massy1,2, Kurt Højlund3,4, Katarina Lalic5, Francesca Porcellati6, Jacqueline Dekker7,
John Petrie8, Gemma Currie8 and Beverley Balkau1,9*
Abstract
Background: People with chronic renal disease are insulin resistant. We hypothesized that in a healthy population,
baseline renal function is associated with insulin sensitivity three years later.
Methods: We studied 405 men and 528 women from the European Group for the study of Insulin Resistance -
Relationship between Insulin Sensitivity and Cardiovascular disease cohort. Renal function was characterized by the
estimated glomerular filtration rate (eGFR) and by the urinary albumin-creatinine ratio (UACR). At baseline only, insulin
sensitivity was quantified using a hyperinsulinaemic-euglycaemic clamp; at baseline and three years, we used surrogate
measures: the Matsuda insulin sensitivity index (ISI), the HOmeostasis Model Assessment of Insulin Sensitivity (HOMA-
IS). Associations between renal function and insulin sensitivity were studied cross-sectionally and longitudinally.
Results: In men at baseline, no associations were seen with eGFR, but there was some evidence of a positive
association with UACR. In women, all insulin sensitivity indices showed the same negative trend across eGFR classes,
albeit not always statistically significant; for UACR, women with values above the limit of detection, had higher clamp
measured insulin sensitivity than other women. After three years, in men only, ISI and HOMA-IS showed a U-shaped
relation with baseline eGFR; women with eGFR> 105 ml/min/1.73m2 had a significantly higher insulin sensitivity than
the reference group (eGFR: 90–105 ml/min/1.73m2). For both men and women, year-3 insulin sensitivity was higher in
those with higher baseline UACR. All associations were attenuated after adjusting on significant covariates.
Conclusions: There was no evidence to support our hypothesis that markers of poorer renal function are associated
with declining insulin sensitivity in our healthy population.
Keywords: Albuminuria, Cohort, Epidemiology, Glomerular filtration rate, Insulin sensitivity, Renal function, Sex
Background
Many studies have investigated the relation between
chronic kidney disease (CKD) and insulin sensitivity, but it
is still not clear whether reduced insulin sensitivity precedes
CKD or the inverse. Most of the epidemiological studies
are cross-sectional, so they cannot resolve this issue, and
the few prospective studies have approached the question
from the hypothesis that low insulin sensitivity precedes, or
perhaps causes, the decline in kidney function.
Early clinical studies focused on insulin sensitivity
in people with CKD and used labor intensive methods
such as the hyperinsulinemic-euglycaemic clamp, the
reference method, to measure insulin sensitivity. De
Fronzo et al. reported in a study of 17 people with
chronic uremia but without diabetes, and 36 controls,
that peripheral insulin resistance was the primary
cause of insulin resistance, not hepatic insulin resist-
ance [1]. Fliser et al. investigated insulin sensitivity by
the frequently sampled intravenous glucose tolerance
test in people at various stages of renal disease [2]. In
this small study of 50 people, there was a trend for
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lower insulin sensitivity in the group with the highest
plasma creatinine levels.
There are a number of large cross–sectional epidemio-
logical studies on insulin resistance with either estimated
glomerular filtration rate (eGFR) and/or CKD [3–12].
Most found a relation between either eGFR or the
prevalence of CKD with insulin resistance measured by
the HOmeostasis Model Assessment of Insulin Resist-
ance (HOMA-IR) [13] or by insulin concentrations, but
not always after adjustment for confounders [5, 10, 11].
There are prospective studies that investigate whether
low insulin sensitivity precedes CKD or a decline in
eGFR [8, 14–17]. Some show that a lower insulin sensi-
tivity is associated with progression to incident CKD
[15–17], one shows a decline in eGFR but no relation
with incident CKD [8], and Fox et al. do not show any
statistically significant relation [14]. An article from the
EGIR-RISC cohort [18] reports that a higher baseline in-
sulin sensitivity is associated with a lower urinary albu-
min creatinine ratio (UACR) at 3 years [19].
The possibility that renal function causes a lowering in
insulin sensitivity needs to be explored. Further, whether as-
sociations differ between men and women is rarely investi-
gated. Cardiovascular risk factors and insulin sensitivity
differ between men and women in the European Group for
the study of Insulin Resistance - Relationship between Insu-
lin Sensitivity and Cardiovascular disease (EGIR-RISC) co-
hort [18] with sex-specific relations between insulin
sensitivity and intima-media thickness parameters, blood
pressure and sleep characteristics [20–22].
We investigate in a healthy population, whether renal
function, as measured by eGFR and UACR, is associated
with insulin sensitivity after three years of follow-up.
Methods
The cohort EGIR-RISC aimed to evaluate whether insu-
lin resistance is involved in the development of cardio-
vascular diseases, in a population without diabetes,
hypertension, renal disease or dyslipidaemia [18]. The
study was approved by ethics committees in each re-
cruitment centre, the declaration of Helsinki was ad-
hered to and participants gave written informed consent
to participate in the study.
The 1259 men and women included in the study were
aged 30 to 60 years (flow chart of inclusions Add-
itional file 1: Figure S1). Criteria for non-inclusion were
renal disease (participants responded to the question
whether they had ‘kidney failure, kidney dialysis or
transplant’ and from study results of eGFR and UACR),
diabetes (treated or from the results of an oral glucose
tolerance test (OGTT)), hypertension, dyslipidaemia or
treatment for any of these pathologies [18].
The population for the present study included 405
men and 528 women who had measures of creatinine
and a clamp measure of insulin sensitivity at baseline. In
this healthy population, none of the individuals had
macroalbuminuria at inclusion (UACR ≥300 mg/mmol)
and the lowest eGFR was 59 ml/min/1.73 m2.
At baseline and 3 years
Participants completed questionnaires detailing smoking
habits, alcohol intake, physical activity, and weight,
height, blood pressures, heart rate were measured. They
underwent a 120 min OGTT, with blood drawn every
30 min, for assays of glucose and insulin. Plasma and
serum samples were frozen at − 80 °C and all assays
were centralized [18].
The glomerular filtration rate was estimated using the
Chronic Kidney Disease EPIdemiology collaboration
equation (CKD-EPI) [23]. This was analysed as a con-
tinuous variable and in three classes eGFR < 90; 90–105;
> 105 ml/min/1.73m2; the threshold 90 ml/min/1.73m2
was chosen as it is conventionally used to indicate kid-
ney disease without chronic kidney failure [23]; the
group with eGFR > 105 ml/min/1.73m2 includes half of
our healthy population. At baseline, the UACR was de-
termined on two separate occasions several weeks apart,
and the mean UACR calculated and analysed in three
classes: undetected, detected below and detected above
the sex-specific median.
The reference method of measuring insulin sensitivity,
the hyperinsulinaemic-euglycaemic clamp [1, 18, 24] was
used at baseline. This involved an infusion of insulin at
the rate of 240 pmol/min/m2 and every 5 to 10 min,
the glucose infusion rate was adjusted so that the con-
centration remained within 0.8 mmol/l of the target glu-
cose concentration, set between 4.5 and 5.5 mmol/l [18].
M/I quantified insulin sensitivity, where M is the glucose
infusion rate and I the insulin concentration over the
last 40 min of the 2-h clamp. The two surrogate mea-
sures of insulin sensitivity were the Matsuda Insulin
Sensitivity Index (ISI) [25]:
ISI ¼ 10; 000=f√½ fasting plasma insulinð Þ x
fasting plasma insulinð Þ
x ð mean OGTT glucose concentrationÞ
x mean OGTT insulin concentrationð Þ 
and the HOmeostasis Model Assessment of Insulin Sen-
sitivity (HOMA-IS = 1/HOMA-IR) [13]:
HOMA−IR ¼ fasting plasma insulinð Þ
x fasting plasma insulinð Þ=22:5:
For prospective analyses, the yearly changes in these
two parameters were calculated.
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Glucose and insulin were assayed at the Odense Uni-
versity hospital in Denmark, by respectively, glucose
oxydase and immunofluorescence techniques.
Creatinine was assayed from frozen samples in the
Centre for Cardiovascular Research in Glasgow, United
Kingdom, using an enzymatic isotope dilution mass
spectrometry standardized method.
Urinary albumin and creatinine were assayed in
Amsterdam at baseline and at 3 years, using a Beckmen
array 360 protein analyser, and a Jaffe creatinine reagent
on a modular P system (Roche).
The lipid profile was from the biochemistry laboratory in
Dublin, Ireland. Total cholesterol, HDL-cholesterol and tri-
glycerides were assayed by enzymatic colorimetric tech-
niques (Roche cholesterol method for modular systems,
Roche HDL 2ndGenmethod for modular systems and
Roche Triglycerides method for modular systems respect-
ively); LDL-cholesterol was calculated from the Friedwald
formula. Leptin and adiponectin were assayed respectively,
by the immunologic DELFIA® method in the department of
clinical biochemistry in Cambridge, UK and by immuno-
flurorescence in the biochemical laboratory, University of
Aarhus, Denmark. Liver enzymes were assayed by the Berg-
meyeres method, according to the International Federation
of Clinical Chemistry recommendations for alanine amino-
transferase (ALAT) and aspartate aminotransferase (ASAT)
and by an enzymatic colorimetric method for gamma gluta-
myltransferase (GGT) in Glasgow; at baseline only,
interleukin-6 (IL-6) and 25 hydroxy vitamin D were also
assayed in Glasgow, by respectively, an ELISA method and
by the ‘competitive principle’ on a Roche/Hitachi Cobas c
311 (Burgess Hill).
Statistical analysis
Characteristics of participants are presented as the median
(first and third quartiles) or as n (percentage).
Kruskal-Wallis and χ2 tests compared the characteristics of
those included and not included in the study, and also com-
pared men and women. At baseline, Spearman partial cor-
relation coefficients quantified the association between the
three measures of insulin sensitivity, adjusted on age and the
recruitment centre. The insulin sensitivity parameters (M/I,
ISI and HOMA-IS) were log-transformed before analysis.
All analyses were stratified on sex, as the regression
analysis of ln(M/I) on eGFR showed a trend for a sex
interaction (Pinter = 0.068).
Cross-sectional associations of insulin sensitivity as
dependent variables, with renal function indicators (eGFR
as a continuous variable and in classes, UACR in classes)
and potential covariates were studied, one-by-one, using
general estimating equation methods, adjusted on age and
recruitment centre, as a random factor. Fractional polyno-
mial transformations were allowed if statistically signifi-
cant [26, 27] and multivariable results used a backwards
stepwise selection procedure to select variables associated
with insulin sensitivity. Only linear functions of eGFR
were chosen by the fractional polynomial transformation
procedure.
The relation between renal function markers at base-
line with ISI and the HOMA-IS indices at year-3, and
their yearly changes, were studied with similar methods.
Analyses used SAS version 9.3 and STATA version 12.
Statistical tests were two-sided and P < 0.05 was consid-
ered statistically significant; we have used a more liberal
value for the interaction as interaction tests are known
to be lacking in power.
Results
Baseline characteristics
The 933 participants studied were older (median 44 vs
41 years) than the 326 not-studied, with a more healthy
profile, a better insulin sensitivity on all three indices,
but no differences for eGFR or UACR (Additional file 1:
Table S1). The median eGFR was 106 ml/min/1.73m2
and only one person had an eGFR under 60 ml/min/
1.73m2, three people had an eGFR > 150 ml/min/1.73m2;
18 individuals (2%) had microalbuminuria, and none
macroalbuminuria.
Most characteristics differed between men and women
(Table 1) with a worse profile in the men. An exception
was eGFR where there was no sex-difference, but the
mean UACR was lower in men than women.
The two surrogate indices of insulin sensitivity were
correlated with the clamp measure (M/I), with Spearman
correlation coefficients, adjusted for age and recruitment
centre of 0.62 and 0.60 for the Matsuda Insulin Sensitiv-
ity Index (ISI), in men and women respectively and 0.50
and 0.49 for HOMA-IS (Additional file 1: Table S2).
Cross–sectional analyses
For men, there was no relation between eGFR and insu-
lin sensitivity. However, over the three UACR classes
there was a statistically significant linear trend for M/I,
with high UACR being associated with higher insulin
sensitivity (P = 0.050) (Fig. 1); similar but non-significant
relations were seen for ISI and HOMA-IS. A number of
variables were related with the three insulin sensitivity
indices, notably physical activity, body mass index
(BMI), heart rate, lipids, adiponectin, leptin, transami-
nases, IL-6, vitamin D (Additional file 1: Table S3). After
adjusting for significant covariates, none of the relations
between renal function markers and insulin sensitivity
indices approached statistical significance. eGFR and
UACR had a low Spearman correlation coefficient of
0.018, and when both were included in a multivariable
regression equation, neither was significant and there
was no interaction.
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For women, eGFR was associated with clamp based
insulin sensitivity – the lower the eGFR, the higher
the insulin sensitivity (Fig. 2), a linear association that
remained after adjusting for covariates (P = 0.005).
For the two other insulin sensitivity indices, there
was a tendency for a trend, but after further adjust-
ment these relations were attenuated. Women with a
detectable UACR had a higher M/I than women with
a low non-detected UACR, but this association was
attenuated after multiple adjustment. The two other
Table 1 Characteristics [median (quartile 1- quartile3) or n (%)] of the study population at inclusion, by sex. The P-values are from
Kruskal Wallis or χ2 tests. The EGIR-RISC Study
Characteristics Men (n = 405) Women (n = 528) P-value
Age (years) 43 (37–51) 45 (39–50) 0.082
Current smoker 108 (27%) 131 (25%) 0.52
Alcohol (g/week) 79 (39–153) 35 (11–68) <.0001
Physical activity (met-mins/week) 2331 (1040–4599) 2165 (1032–4958) 0.92
BMI (kg/m2) 25.7 (23.8–27.9) 23.9 (21.9–26.8) <.0001
Systolic blood pressure (mmHg) 122 (115–130) 114 (104–122) <.0001
Heart rate (bpm) 64 (58–72) 70 (63–77) <.0001
Renal function parameters
Creatinine (μmol/l) 75 (67–83) 59 (51–66) <.0001
Estimated glomerulaire filtration rate (ml/min/1.73 m2) 106 (98–114) 106 (96–114) 0.53
< 90 61 (15%) 78 (15%)
90 to 104.9 120 (29%) 167 (31%) 0.81
≥ 105 224 (56%) 283 (54%)
Urinary albumin-creatinine ratio (mg/mmol) 0.18 (0–0.35) n = 520
0.26 (0–0.47)
0.001
not detected 104 (26%) 139 (27%)
detected but < 0.26/0.36 men/women 148 (36%) 187 (36%) 0.94
≥ 0.26/0.36 men/women 153 (38%) 194 (37%)
Insulin sensitivity indices
M/I (μmol/min/Kg.ffm/nM) 114 (85–154) 147 (112–192) <.0001
ISI 9.0 (6.5–12.8) 9.6 (6.6–13.9) 0.038
HOMA-IS 14 (10–20) 16 (11–24) 0.0036
Biological characteristics
Fasting glucose (mmol/l) 5.2 (4.9–5.5) 5.0 (4.7–5.3) <.0001
2 h glucose (mmol/l) 5.5 (4.6–6.5) 5.6 (4.7–6.7) 0.033
Fasting insulin (pmol/l) 30 (22–44) 29 (20–40) 0.060
2 h insulin (pmol/l) 124 (73–216) 152 (102–242) <.0001
Total cholesterol (mmol/l) 4.9 (4.3–5.4) 4.8 (4.2–5.3) 0.065
LDL-cholesterol (mmol/l) 3.0 (2.6–3.6) 2.8 (2.3–3.3) <.0001
HDL-cholesterol (mmol/l) 1.2 (1.1–1.4) 1.6 (1.3–1.8) <.0001
Triglycerides (mmol/l) 1.1 (0.8–1.5) 0.8 (0.6–1.1) <.0001
Adiponectin (mg/l) 6.2 (4.7–7.8) 9.3 (7.2–12.2) <.0001
Leptin (ng/ml) 4.6 (2.2–7.5) 14.6 (9.4–24.4) <.0001
Alanine aminotransferase (IU/l) 16 (12–22) 11 (8–15) <.0001
Aspartate aminotransferase (IU/l) 22 (17–27) 18 (14–23) <.0001
Gamma glutamyltransferase (IU/l) 19 (13–29) 12 (8–17) <.0001
Interleukin-6 (pg/ml) 0.74 (0.50–1.17) 0.68 (0.49–1.12) 0.12
25-OH vitamin D (ng/ml) 21 (14–28) 19 (12–27) 0.0079
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Fig. 1 (See legend on next page.)
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insulin sensitivity indices were not associated with
UACR.
Thus, for men there was no association between eGFR
and clamp measured insulin sensitivity, for women there
was a statistically significant inverse association.
Prospective analyses, does renal function predict insulin
sensitivity?
Over the three years of follow up, the two measures of
insulin sensitivity decreased, eGFR decreased, UACR in-
creased (Additional file 1: Table S4), with no differences
between men and women.
For men, at three years both insulin sensitivity indices
showed a U shaped relation with baseline eGFR: high
and low eGFR groups had higher insulin sensitivity than
the reference group; this relation remained for the
3-year HOMA-IS, after adjustment for covariates
(Table 2). The yearly change, ΔISI, was higher for base-
line eGFR> 105 ml/min/1.73m2 in comparison with the
reference group, and this remained statistically signifi-
cant after adjustment. Higher levels of baseline UACR
were associated with a better insulin sensitivity at year-3,
with HOMA-IS showing a stronger association that
remained significant after adjustment for confounders.
There was little evidence of association with the changes
in insulin sensitivity and baseline UACR.
For women, baseline eGFR was linearly associated with
3-year ISI, the lower eGFR, the higher ISI, similar to the
cross-sectional results, but this lost statistical signifi-
cance after adjustment (Table 3). A higher baseline eGFR
was associated with a greater positive ΔHOMA-IS, and
this association was a little attenuated after adjustment.
A higher baseline UACR was associated with higher
3-year ISI and HOMA-IS, and higher increases in both
ΔISI and ΔHOMA-IR, and most of these relations
remained significant after adjustment.
Discussion
Data from the EGIR-RISC study did not confirm our hy-
pothesis, that worsening markers of renal function (eGFR
and UACR) precede declining insulin sensitivity in a healthy
population, with renal markers within the normal range. In
fact, we observed associations between a higher insulin sen-
sitivity and markers of a worsening renal function.
In cross-sectional analyses, the insulin sensitivity indi-
ces were not related with markers of renal function in
men, except for higher insulin sensitivity in those with
higher UACR; this was no longer significant after
adjustment for covariates. In women, clamp measured
insulin sensitivity was higher in those with a lower
eGFR, and this linear association remained after adjust-
ment; clamp measured insulin sensitivity was also higher
in women with detectable UACR, but this relation was
attenuated after adjustment.
In longitudinal analyses, men with a higher and a
lower eGFR had a higher insulin sensitivity at year-3
than the reference group (eGFR 90–105 ml/min/1.732).
In agreement, larger increases in ΔISI and ΔHOMA-IS
were also related with a low eGFR. These relations
remained consistent after adjustment for covariates. The
higher the baseline UACR, the higher the year-3 insulin
sensitivity. For women, there were no such relations be-
tween baseline eGFR and insulin sensitivity indices, but
as for men, the higher the baseline UACR the higher the
3-year insulin sensitivity.
In the literature, the relation between insulin resistance
and renal function has mainly been studied in people with
renal disease, who were compared to people without renal
disease. Cross-sectional studies have reported that insulin
resistance exists in people without diabetes but with chronic
kidney disease. DeFronzo showed that peripheral insulin re-
sistance is present in people with chronic renal failure, but
hepatic insulin resistance may not be impaired [1]. Periph-
eral insulin sensitivity is essentially insulin sensitivity in skel-
etal muscle [28]. HOMA-IS is based on fasting glucose and
fasting insulin, and reflects hepatic insulin sensitivity, but
could also reflect insulin clearance. ISI uses insulin and glu-
cose levels during the two-hour oral glucose tolerance test,
providing a dynamic estimate, reflecting both hepatic and
peripheral insulin sensitivity [29]. The correlations between
the clamp based insulin sensitivity measure and the surro-
gate indices were 0.50–0.60, similar to other studies.
The earliest publication in a population without diabetes
or renal disease comes from Japan; a significant positive as-
sociation was seen between insulin levels and serum cre-
atinine [3]. In the American NHANES III study, Chen et al.
described a higher prevalence of chronic renal disease
(eGFR< 60 ml/min/1.73m2) in people without diabetes but
with a low insulin sensitivity (odds ratio 2.6 for HOMA-IR
above the upper quartile in comparison with below the
lower quartile) [4]. Another analysis from the same popula-
tion showed that HOMA-IR was related with eGFR in men,
but not in women [5]. In older populations with lower
eGFR, associations were seen with insulin resistance [6, 8,
9], whereas no association was seen in a healthy population
[7]. In a study of a Korean population, Park et al. conclude
(See figure on previous page.)
Fig. 1 Differences in mean values (standard errors) of baseline insulin sensitivity according to baseline renal function markers in men from the
EGIR-RISC Study with reference groups (90–105 ml/min/1.73m2) for eGFR, not detected for UACR), adjusted for age and recruitment centre, and
then multiply adjusted for significant covariates: triglycerides, adiponectin, leptin and for the other parameters shown in the six individual figures.
P-values are shown comparing groups when P < 0.1: full lines for age and centre adjusted and dotted lines for multiple adjustment
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that “there were no meaningful differences in HOMA-IR
according to eGFR group” [11]. The results from these
cross-sectional studies are not consistent, and this may be
due to the age of the study populations, the numbers with
low eGFR, the population studied (with or without diabetes,
the metabolic syndrome [12], according to BMI [10], the
level of eGFR used to define chronic kidney disease) as well
as the covariates used for adjustment. Our EGIR-RISC
cohort is younger, only 15% had an eGFR < 90 ml/min/
1.73m2 and hypertension was an exclusion criterion.
Some studies have evaluated prospectively, whether a low-
ering of insulin sensitivity precedes a decline in renal func-
tion, but not the reverse relation, that renal decline comes
first. Nerpin et al. investigated the association between insu-
lin sensitivity measured by the hyperinsulinemic-euglycemic
clamp and eGFR based on cystatin-C, in a cohort of Swedish
(See figure on previous page.)
Fig. 2 Differences in mean values (standard errors) of baseline insulin sensitivity according to baseline renal function markers in women from the
EGIR-RISC Study, with reference groups (90–105 ml/min/1.73m2) for eGFR, not-detected for UACR), adjusted by age and recruitment centre, and
then multiply adjusted for significant covariates: triglycerides, adiponectin, leptin and for the other parameters shown in the six individual figures.
P-values are shown comparing groups when P < 0.10: full lines for age, centre adjusted and dotted lines for multiple adjustment
Table 2 Differences (95% confidence intervals) in 3-year insulin sensitivity indices (ISI and HOMA-IS) and their 3-year changes (ΔISI,
ΔHOMA-IS) associated with one unit or class increase in baseline renal function parameters (estimated glomerular filtration rate
(eGFR), urinary creatinine ratio (UACR)) Model 1: adjusted for recruitment centre (random effect) and age; Model 2: additionally
adjusted for significant baseline variables, as indicated in the footnotea. The EGIR-RISC Study - Men
ln (ISI year 3) Ln (HOMA-IS year 3) ΔISI ΔHOMA-IS
difference (95% CI) P difference (95% CI) P difference
(95% CI)
P difference
(95% CI)
P
eGFR (ml/min/1.73 m2) n = 376 n = 392 n = 349 n = 380
Model 1 trend 0.34 trend 0.35 trend 0.11 trend 0.47
eGFR> 105 .15
(.01, .30)
0.041 .093
(.030,.157)
0.004 1.5
(.2, 2.8)
0.015 2.1
(−1.2, 5.4)
0.21
eGFR 90–105 0 0 0 0
eGFR < 90 .14
(−.05, .33)
0.13 .094
(.014, .173)
0.021 .65
(−.90, 2.20)
0.41 1.7
(−2.6,6.0)
0.43
Model 2a trend 0.44 trend 0.66 trend 0.11 trend 0.21
eGFR > 105 .10
(−.01,.21)
0.069 .064
(.014, .115)
0.011 1.6
(.4, 2.9)
0.010 3.2
(−.1,6.5)
0.053
eGFR 90–105 0 0 0 0
eGFR < 90 .038
(−.097, .174)
0.58 .058
(−.004, .121)
0.064 .75
(−.80, 2.30)
0.34 1.6
(−2.6, 5.7)
0.45
UACR (mg/mmol) n = 376 n = 392 n = 349 n = 380
Model 1 trend 0.026 trend 0.001 trend 0.49 trend 0.22
UACR not detected 0 0 0 0
UACR detected but < 0.26 −.002
(−.153, .149)
0.98 .032
(−.033, .098)
0.33 −.57
(−1.84, 0.72)
0.39 −.26
(−3.72, 3.21)
0.88
UACR ≥ 0.26 .16
(.00, .31)
0.039 .10
(.03,.17)
0.002 .34
(−.92, 1.62)
0.59 1.9
(−1.4, 5.4)
0.26
Model 2a trend 0.38 trend 0.009 trend 0.38 trend 0.050
UACR not detected 0 0 0 0
UACR detected but < 0.26 −.027
(−.139, .084)
0.63 .026
(−.024, .077)
0.31 −.51
(−1.78, .78)
0.44 .66
(−2.70,4.03)
0.70
UACR≥ 0.26 .042
(−.068, .152)
0.45 .064
(.014, .114)
0.011 .47
(−.80,1.74)
0.47 3.2
(−.1,6.5)
0.062
aMultivariable models adjusted on age and recruitment centre, and on other significant covariates:
ln (ISI year3) and eGFR, adjusted on: HDL-cholesterol, trigylcerides, adiponectin, leptin ALAT, Il-6
ln (ISI year3) and UACR, adjusted on: HDL-cholesterol, trigylcerides, adiponectin, leptin ALAT
ln (HOMA-IS year 3) and eGFR, adjusted on: alcohol consumption, triglycerides, adiponectin, leptin, ALAT, IL-6
ln (HOMA-IS year 3) and UACR, adjusted on: alcohol consumption, heart rate, HDL-cholester ol, triglycerides, adiponectin, leptin, ALAT
ΔISI and eGFR, UACR, adjusted on: leptin
ΔHOMA-IS and eGFR, UACR, adjusted on: alcohol consumption, GGT
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men, average age 71 years [16]. They show that a higher in-
sulin sensitivity at baseline is associated with a lower risk of
impaired renal dysfunction (eGFR< 50 ml/min/1.73m2) over
the 7 years of the study, independently of other aspects of
glucose metabolism. In the EGIR-RISC cohort, we have
shown that a low baseline clamp-based insulin sensitivity is
associated with a higher UACR measured at year-3 [19].
In the light of these publications, insulin sensitivity ap-
pears to be related with chronic renal disease in those
with a compromised renal function. However, in our
population of healthy people, this association was not
apparent and none of the relations we observed were
present in both sexes, and were not always concordant
when the variables measuring renal function were ana-
lysed as continuous or as discrete variables. Sechi et al.
showed that alterations of glucose metabolism in people
with essential hypertension, are only evident for eGFR<
50 ml/min/1.73m2 and this may be the reason why our
results are not conclusive [30].
Our results on UACR are unexpected, as a high base-
line UACR, in comparison to an undetected level, was
related with a higher insulin sensitivity three years later,
and this was the case for men and women. UACR did
increase over the three years of the study, as expected.
While we have used UACR as a renal marker, it is also a
marker of vascular function.
Table 3 Differences (95% confidence intervals) in 3-year insulin sensitivity indices (ISI and HOMA-IS) and their 3-year changes (ΔISI,
ΔHOMA-IS) associated with one unit or class increase in baseline renal function parameters (estimated glomerular filtration rate
(eGFR), urinary creatinine ratio (UACR)) Model 1: adjusted for recruitment centre (random effect) and age; Model 2: additionally
adjusted for significant baseline variables, as indicated in the footnotea. The EGIR-RISC Study - Women
ln (ISI year 3) ln (HOMA-IS year 3) ΔISI ΔHOMA-IS
difference (95% CI) P difference (95% CI) P difference
(95% CI)
P difference
(95% CI)
P
eGFR (ml/min/1.73 m2) n = 492 n = 514 n = 448 n = 501
Model 1 trend 0.050 trend 0.15 trend 0.46 trend 0.40
eGFR > 105 −.086
(−.200, .028)
0.14 −.027
(−.150, .096)
0.67 .81
(−.35, 1.97)
0.17 2.5
(0.2, 4.8)
0.032
eGFR 90–105 0 0 0 0
eGFR < 90 .050
(−.101, .201)
0.51 .072
(−.084, .228)
0.37 1.1
(−.4, 2.6)
0.12 .74
(−2.10, 3.58)
0.61
Model 2a trend 0.29 trend 0.55 trend 0.55 trend 0.55
eGFR > 105 −.050
(−.146, .047)
0.31 −.010
(.-.11, .09)
0.84 .76
(−.37, 1.91)
0.19 2.19
(−0.06, 4.44)
0.057
eGFR 90–105 0 0 0 0
eGFR < 90 .011
(−.108, .131)
0.86 .016
(−.110, .141)
0.81 1.02
(−.37, 2.42)
0.15 .75
(−2.06, 3.57)
0.60
UACR (mg/mol) n = 486 n = 507 n = 442 n = 494
Model 1 trend 0.009 trend 0.023 trend 0.063 trend 0.004
UACR not detected ref ref ref ref
UACR detected but < 0.36 .11
(−.01, .24)
0.080 .11
(−.02, .24)
0.10 .57
(−.60, 1.75)
0.34 .69
(−1.66, 3.03)
0.56
UACR≥ 0.36 .16
(.04, .29)
0.008 .15
(.02 .28)
0.021 1.11
(−0.06, 2.29)
0.064 3.33
(.99, 5.698)
0.005
Model 2a trend 0.029 trend 0.21 trend 0.044 trend 0.007
UACR not detected ref ref ref ref
UACR detected but < 0.36 .044
(−.056, .145)
0.38 .022
(−.080, .125)
0.67 .69
(−.48, 1.85)
0.25 .56
(−1.77, 2.88)
0.64
UACR ≥ 0.36 .11
(.008, .21)
0.032 .063
(−.038, .164)
0.22 1.20
(.03, 2.37)
0.044 3.1
(0.7, 5.4)
0.010
aMultivariable models adjusted on age and recruitment centre, and on other significant covariates:
Ln(ISI year 3) and eGFR, adjusted on: current smoker, BMI, heart rate, HDL cholesterol, triglycerides, adiponectin, leptin, GGT
Ln(ISI year 3) and UACR, adjusted on: current smoker, BMI, heart rate, HDL cholesterol, triglycerides, adiponectin, leptin
Ln(HOMA-IS year 3) and eGFR adjusted on: physical activity, BMI, heart rate, HDL-cholesterol, triglycerides, adiponectin, leptin
Ln(HOMA-IS year 3) and UACR adjusted on: alcohol consumption, physical activity, BMI, heart rate, HDL-cholesterol, triglycerides,
adiponectin, leptin
ΔISI and eGFR, UACR, adjusted on: LDL-cholesterol, ALAT
ΔHOMA-IS and eGFR, UACR, adjusted on: LDL-cholesterol
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What are the possible mechanisms for an association
between insulin sensitivity and chronic kidney disease?
Low insulin sensitivity (as measured by the minimal
model technique) has been described in people with renal
disease but a normal eGFR (evaluated by inulin clearance);
insulin sensitivity was similar across the range of eGFR
[2]. These results imply that renal dysfunction, could pre-
cede the onset of declining insulin sensitivity. A rhesus
monkey model provides additional arguments [31]. Recent
studies have identified specific uremic toxins that could
mediate an association between chronic renal disease and
insulin sensitivity, toxins such as p-cresyl sulfate a protein
in the intestinal microbiota [32].
In our healthy cohort, we showed that a higher filtra-
tion: eGFR (≥105 ml/min/1.73m2) was associated,
cross-sectionally, with lower insulin sensitivity in women.
This result is not so surprising as insulin resistance pre-
cedes the development of diabetes, which in turn is associ-
ated with a higher glomerular filtration rate [33].
However, the reverse was the case in men for our pro-
spective study, as those with a higher eGFR were more
likely to have a higher 3-year insulin sensitivity and a more
pronounced increase in insulin sensitivity than the refer-
ence group, even if in the whole population both eGFR
and insulin sensitivity decreased over time.
The multicentre aspect of this study is one of its
strengths, as the study population covered a range of
European lifestyles and diets. Differences between cen-
tres were accounted for in analyses by a random effect.
At inclusion, insulin sensitivity was measured by the
hyperinsulinemic-euglycemic clamp, a procedure that was
carefully standardised across the European centres, for this
large cohort study, with more than 1300 participants. All
biological assays in the EGIR-RISC study are from central
laboratories. At baseline the UACR was measured on two
occasions and the mean used, leading to a more precise es-
timate. Another force is that there is little missing data in
this study, and for the few variables where data were miss-
ing, we imputed with the sex-specific median value.
Our study differs from other studies in that all ana-
lyses have been done for men and women separately.
This was justified by their differences in characteristics,
and the study of interactions with sex. Other EGIR-RISC
analyses have shown differences between men and
women [20–22]. It is also unique in that we studied a
cohort of healthy individuals, without chronic renal dis-
ease, diabetes, hypertension or dyslipidaemia.
The EGIR-RISC study has a number of limitations.
The study population consists of healthy volunteers,
and thus is not representative of the general healthy
population of the same age. Further, as we excluded
people who were not present at the three-year exam-
ination, we have selected an even healthier popula-
tion, according to their characteristics at baseline.
With the surrogate measures of insulin sensitivity, we
were not able to precisely evaluate insulin sensitivity
and its change over the three year follow-up period,
even if the correlations with clamp based insulin sen-
sitivity were of the order of 0.6. One of the major
limitations of the EGIR-RISC study is that it is a very
healthy population with only 15% of our population
having an eGFR< 90 ml/min/1.73m2. There are likely
to be only very small changes in parameters over
three years in such a population, so a much longer
follow-up would be required to show associations.
Conclusion
Insulin sensitivity in the absence of chronic kidney dis-
ease (eGFR< 60 ml/min/1.73 m2) and without other
markers of kidney damage, such as microalbuminuria, is
not associated with a declining glomerular filtration rate.
Our study is the only one, to our knowledge, that evalu-
ates in a prospective study, insulin sensitivity as a func-
tion of baseline renal function. A longer prospective
study evaluating insulin sensitivity by the reference
method, both at baseline and at follow-up, over a range
of eGFR values is needed to understand the physiopa-
thology of change in insulin sensitivity in people with
and without chronic kidney disease.
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